Show legend Show as text

Structure type: polymer chemical repeating unit
Compound class: O-polysaccharide, glycoside
Contained glycoepitopes: IEDB_140629,IEDB_142488,IEDB_144998,IEDB_146664,IEDB_420419,IEDB_420420,IEDB_420421,IEDB_857742,IEDB_983931,SB_192

• Article ID: 7617
  Fujioka-Kobayashi M, Ota MS, Shimoda A, Nakahama K, Akiyoshi K, Miyamoto Y, Iseki S "Cholesteryl group- and acryloyl group-bearing pullulan nanogel to deliver BMP2 and FGF18 for bone tissue engineering" - Biomaterials 33(30) (2012) 7613-7620
  

  To create a drug delivery system that allows the controlled release of proteins, such as growth factors, over a long-term period, cholesteryl group- and acryloyl group-bearing pullulan (CHPOA) nanogels were aggregated to form fast-degradable hydrogels (CHPOA/hydrogels) by cross-linking with thiol-bearing polyethylene glycol. The gold standard of clinical bone reconstruction therapy with a physiologically active material is treatment with recombinant human bone morphogenetic protein 2 (BMP2); however, this approach has limitations, such as inflammation, poor cost-efficiency, and varying interindividual susceptibility. In this study, two distinct growth factors, BMP2 and recombinant human fibroblast growth factor 18 (FGF18), were applied to a critical-size skull bone defect for bone repair by the CHPOA/hydrogel system. The CHPOA-FGF18/hydrogel displayed identical results to the control CHPOA-PBS/hydrogel, and the CHPOA-BMP2/hydrogel treatment imperfectly induced bone repair. By contrast, the CHPOA-FGF18 + BMP2/hydrogel treatment strongly enhanced and stabilized the BMP2-dependent bone repair, inducing osteoprogenitor cell infiltration inside and around the hydrogel. This report indicates that the CHPOA/hydrogel system can successfully deliver two different proteins to the bone defect to induce effective bone repair. The combination of the CHPOA/hydrogel system with the growth factors FGF18 and BMP2 might be a step towards efficient bone tissue engineering.

  drug delivery, acryloyl group-modified cholesterol-bearing pullulan (CHPOA), bone regeneration, osteoblasts, recombinant human bone morphogenetic protein 2 (BMP2), recombinant human fibroblast growth factor 18 (FGF18)

  NCBI PubMed ID: 22800537
  Publication DOI: 10.1016/j.biomaterials.2012.06.075
  Journal NLM ID: 8100316
  Publisher: Amsterdam: Elsevier
  Correspondence: s.iseki.emb@tmd.ac.jp
  Institutions: Section of Molecular Craniofacial Embryology, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Tokyo, Japan, Department of Oral Surgery, Subdivision of Molecular Oral Medicine, Division of Integrated Sciences of Translational Research, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan, Global Center of Excellence (GCOE) Program, International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo, Japan, Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan, Cellular Physiological Chemistry, Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Tokyo, Japan
  Methods: X-ray, biological assays, derivatization
  
   
  
  Aureobasidium pullulans
  CSDB ID 44472 (all data & tools)

Show legend Show as text

Structure type: structural motif or average structure
Compound class: O-polysaccharide, glucan, glucoside
Contained glycoepitopes: IEDB_140629,IEDB_142488,IEDB_144998,IEDB_146664,IEDB_420419,IEDB_420420,IEDB_420421,IEDB_857742,IEDB_983931,SB_192

• Article ID: 7624
  Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E "Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination" - International Journal of Cancer 130(3) (2012) 584-592
  

  NY-ESO-1 is a prototypic cancer/testis antigen. In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1-expressing tumors with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and showed efficient induction of NY-ESO-1 antibody, and CD4 and CD8 T cell responses using peripheral blood from the patients. In our study, we analyzed heteroclitic serological responses in those patients after vaccination. Serological response against 11 tumor antigens including MAGE-A1, MAGE-A3, MAGE-A4, CT7/MAGEC1, CT10/MAGEC2, CT45, CT46/HORMAD1, SOX2, SSX2, XAGE1B and p53 was examined by enzyme-linked immunosorbent assay (ELISA) using sera from ten vaccinated patients. Expression of tumor antigens was determined by reverse transcription-polymerase chain reaction or immunohistochemistry. Eight of nine patients who showed antibody responses against NY-ESO-1 also showed an antibody response against at least 1 of these 11 tumor antigens after vaccination. In one patient, seven tumor antigens were recognized. Specificity analysis of the antibody response by ELISA using control recombinant proteins and synthetic peptides and by Western blot showed that the response was not against His6-tag and/or bacterial products included in a preparation of CHP-NY-ESO-1 used for vaccination. Thus, heteroclitic serological responses appear to be indicative of the overall immune response against the tumor, and their analysis could be useful for immune monitoring in cancer vaccine.

  cancer vaccine, pullulan, cancer testis antigen, heteroclitic antibody response, NY-ESO-1

  NCBI PubMed ID: 21413013
  Publication DOI: 10.1002/ijc.26074
  Journal NLM ID: 42124
  Publisher: New York, NY: Wiley-Liss
  Correspondence: hwada@gesurg.med.osaka-u.ac.jp
  Institutions: Department of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, Department of Respiratory Medicine, Kawasaki Medical School, Kurashiki, Japan, New York Branch at Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, New York, USA, Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan, Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Melbourne Centre for Clinical Sciences, Ludwig Institute for Cancer Research, Melbourne, Australia, Office of Clinical Trials Management, Ludwig Institute for Cancer Research, New York, USA, Faculty of Health and Welfare, Kawasaki University of Medical Welfare, Kurashiki, Japan
  Methods: ELISA, Western blotting, biological assays, derivatization
  
   
  
  Aureobasidium pullulans
  CSDB ID 44483 (all data & tools)